Human anti-cd33 antibodies and uses thereof
AssigneeFred Hutchinson Cancer Center
InventorsRoland B. Walter, George S. Laszlo
Life of this patent
Estimating the term…
Abstract
A suite of novel human anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33 or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).
Claims53
An antibody or antigen binding fragment thereof comprising a set of complementarity determining regions (CDRs) having
- (i) a CDRL1 having the sequence as set forth in SEQ ID NO:
- 24,
- a CDRL2 having the sequence as set forth in SEQ ID NO:
- 25,
- a CDRL3 having the sequence as set forth in SEQ ID NO:
- 26,
- a CDRH1 having the sequence as set forth in SEQ ID NO:
- 27,
- a CDRH2 having the sequence as set forth in SEQ ID NO:
- 28, and
- a CDRH3 having the sequence as set forth in SEQ ID NO:
- 29;
- (ii) a CDR having the sequence as set forth in SEQ ID NO:
- 183,
- a CDRL2 having the sequence AAS,
- a CDRL3 having the sequence as set forth in SEQ ID NO:
- 26,
- a CDRH1 having the sequence as set forth in SEQ ID NO:
- 184,
- a CDRH2 having the sequence as set forth in SEQ ID NO:
- 185, and
- a CDRH3 having the sequence as set forth in SEQ ID NO:
- 29;
- (iii) a CDRL1 having the sequence as set forth in SEQ ID NO:
- 24,
- a CDRL2 having the sequence as set forth in SEQ ID NO:
- 204,
- a CDRL3 having the sequence as set forth in SEQ ID NO:
- 26,
- a CDRH1 having the sequence as set forth in SEQ ID NO:
- 205,
- a CDRH2 having the sequence as set forth in SEQ ID NO:
- 206, and
- a CDRH3 having the sequence as set forth in SEQ ID NO:
- 207;
- or
- (iv) a CDRL1 having the sequence as set forth in SEQ ID NO:
- 24,
- a CDRL2 having the sequence as set forth in SEQ ID NO:
- 204,
- a CDRL3 having the sequence as set forth in SEQ ID NO:
- 26,
- a CDRH1 having the sequence as set forth in SEQ ID NO:
- 222,
- a CDRH2 having the sequence as set forth in SEQ ID NO:
- 223, and
- a CDRH3 having the sequence as set forth in SEQ ID NO:
- 207.
An antibody or antigen binding fragment thereof comprising a complementarity determining region (CDR) set of 1H10, 1A9, 1E6, 1D2, 1B9, 1H8, 2D3, or 2E3, as defined by IMGT, Kabat, North, or Chothia.
A CD33-targeting agent comprising a binding domain comprising a complementarity determining region (CDR) set of 1H10, 1A9, 1E6, 1D2, 1B9, 1H8, 2D3, or 2E3, as defined by IMGT, Kabat, North, or Chothia as part of an anti-CD33 immunotoxin, an anti-CD33 antibody-drug conjugate, an anti-CD33 antibody-radioisotope conjugate, an anti-CD33 bispecific antibody, an anti-CD33 bispecific immune cell engaging antibody, an anti-CD33 trispecific antibody, and/or an anti-CD33 tetraspecific antibody.
A CD33-targeting agent comprising a binding domain comprising
- the variable light chain and the variable heavy chain of 1H10, 1A9, 1E6, 1D2, 1B9, 1H8, 2D3, or 2E3 or
- a sequence having at least 90% sequence identity to the variable light chain of 1H10, 1A9, 1E6, 1D2, 1B9, 1H8, 2D3, or 2E3 and a sequence having at least 90% sequence identity to the corresponding variable heavy chain of 1H 10, 1A9, 1E6, 1D2, 1B9, 1H8, 2D3, or 2E3
- as part of an anti-CD33 immunotoxin, an anti-CD33 antibody-drug conjugate, an anti-CD33 anti-CD33 antibody-radioisotope conjugate, an anti-CD33 bispecific antibody, an anti-CD33 bispecific immune cell engaging antibody, an anti-CD33 trispecific antibody, and/or an anti-CD33 tetraspecific antibody.
A kit comprising a composition comprising a binding domain of one or more of 1H10, 1A9, 1E6, 1D2, and 1B9 and a binding domain of one or more of one or more of 1H8, 2D3, and 2E3.
A kit comprising a composition comprising a binding domain of one or more of 1H10, 1A9, 1E6, 1D2, and 1B9 and a composition comprising a binding domain of one or more of one or more of 1H8, 2D3, and 2E3.
Dependencies are inferred from the claim text.